Escherichia (e.g., E. Coli, Etc.) Or Salmonella Patents (Class 435/252.8)
-
Publication number: 20120149090Abstract: The invention provides a cell for preparing competent cells, wherein the cell is capable of spontaneously accumulating self-producing trehalose therein and the cell is used for the preparation of competent cells. The invention also provides a method for preparing competent cells, including: culturing the cell for preparing the competent cell mentioned previously to obtain a cell suspension; placing the cell suspension into an ice bath; centrifuging the cell suspension to obtain a cell precipitate; mixing a transform reagent with the cell precipitate; and obtaining competent cells suspension.Type: ApplicationFiled: December 27, 2010Publication date: June 14, 2012Inventors: Jia-Hung WANG, Meng-Yin TSAI, Ting-Ting HUNG, Kelly TENG
-
Publication number: 20120149115Abstract: The present invention relates to a method for genomic DNA rearrangements, and more particularly, to a method for deletion, duplication, inversion, replacement, or rearrangement of genomic DNA using pairs of site-specific nucleases targeting two or more sites in the genome, a cell in which genomic DNA is deleted, duplicated, inverted, replaced, or rearranged by the same method, and a method for expressing the site-specific nucleases in cells. Further, the present invention relates to a method for inserting synthetic DNA molecules into the genome using site-specific nucleases targeting a pre-determined site in the genome, a cell in which DNA insertion occurs by the same method, and a method for expressing the site-specific nucleases in cells.Type: ApplicationFiled: June 11, 2010Publication date: June 14, 2012Applicants: SNU R&DB FOUNDATION, TOOLGEN INCORPORATIONInventors: Jin Soo Kim, Hyung Joo Lee, Eun Ji Kim
-
Patent number: 8198044Abstract: The invention relates to compositions and methods for the in vivo production of polypeptides comprising one or more unnatural amino acids. Specifically, the invention provides plasmid systems for the efficient eubacterial expression of polypeptides comprising one or more unnatural amino acids at genetically-programmed positions.Type: GrantFiled: March 7, 2007Date of Patent: June 12, 2012Assignee: The Scripps Research InstituteInventors: Youngha Ryu, Peter G. Schultz
-
Publication number: 20120141443Abstract: The present invention generally relates to the field of bacteria. In particular, the present invention concerns “short time high temperature” treated probiotics and/or dairy starter cultures and applications of these bacteria. One embodiment of the present invention relates to “short-time high temperature” treated probiotics and/or dairy starter cultures and their use to prepare compositions to treat or prevent inflammatory disorders.Type: ApplicationFiled: May 7, 2010Publication date: June 7, 2012Applicant: NESTEC S.A.Inventors: Guenolee Prioult, Annick Mercenier
-
Publication number: 20120137752Abstract: Hydrotesting fluid compositions including stable populations of corrosion reducing microbes, where the populations are is sufficient to reduce or eliminate microbiologically influenced corrosion (MIC).Type: ApplicationFiled: September 27, 2011Publication date: June 7, 2012Applicants: WEATHERFORD/LAMB, INC.Inventor: Michael Morrow
-
Patent number: 8187850Abstract: The present invention provides a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family, particularly a bacterium belonging to genus Escherichia or Pantoea, which has been modified to attenuate expression of the ybiV gene.Type: GrantFiled: January 30, 2008Date of Patent: May 29, 2012Assignee: Ajinomoto Co., Inc.Inventors: Konstantin Vyacheslavovich Rybak, Marina Evgenievna Sheremet'eva, Aleksandra Yurievna Skorokhodova, Tatyana Viktorovna Leonova, Yury Ivanovich Kozlov, Vitaly Grigorievich Paraskevov, legal representative
-
Publication number: 20120124898Abstract: This invention provides co-cultures of photosynthetic microorganisms and biofuel producing microorganisms. In certain embodiments, polysaccharide-producing, photosynthetic microorganisms are microalgae having frustules provide a substrate on which biofuel-producing microorganisms can grow. In other embodiments, the photosynthetic microorganisms produce a lipid and the non-photosynthetic microorganisms produce a solvent in which the lipid is soluble.Type: ApplicationFiled: July 21, 2011Publication date: May 24, 2012Inventor: Pamela R. Contag
-
Publication number: 20120114698Abstract: The present invention relates to a Salmonella strain suitable as a marker vaccine having an inactivated gene.Type: ApplicationFiled: November 20, 2009Publication date: May 10, 2012Inventor: Heiko Apfel
-
Publication number: 20120100116Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.Type: ApplicationFiled: April 2, 2010Publication date: April 26, 2012Applicants: THOMAS JEFFERSON UNIVERSITY, INSTITUT PASTEURInventors: Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell
-
Publication number: 20120100591Abstract: Fermentation products (e.g., bioproducts such as hydrocarbons and other organic compounds) are produced from biomass or gases through digestion and fermentation under conditions that thermodynamically favor production of the fermentation products.Type: ApplicationFiled: December 3, 2010Publication date: April 26, 2012Inventor: Richard Allen Kohn
-
Publication number: 20120093869Abstract: The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity.Type: ApplicationFiled: May 14, 2010Publication date: April 19, 2012Inventors: David Klumpp, Anthony Schaeffer, Benjamin Billips
-
Patent number: 8153414Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.Type: GrantFiled: December 6, 2000Date of Patent: April 10, 2012Assignee: Allertein Therapeutics, LLCInventors: Michael J. Caplan, Hugh A. Sampson, A. Wesley Burks, H. Kim Bottomly, Howard B. Sosin
-
Patent number: 8148107Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: GrantFiled: June 23, 2011Date of Patent: April 3, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
-
Publication number: 20120077241Abstract: The invention relates to bacterium that have increased resistance to furfural and methods of preparation. The invention also relates to methods of producing ethanol using the bacterium and corresponding kits.Type: ApplicationFiled: January 4, 2010Publication date: March 29, 2012Applicant: University of Florida Research Foundation, Inc.Inventors: Elliot Norman Miller, Laura R. Jarboe, Lorraine P. Yomano, Sean W. York, Keelnatham Shanmugam, Lonnie O'Neil Ingram
-
Publication number: 20120077181Abstract: The cryopreservation of cells and tissue cultures for long term storage of cells, cell constructs or three-dimensional complex tissues assemblies is based on the use of a collagen cell carrier (CCC) having a specific composition and thickness and appropriate mechanical properties which are maintained after thawing. The collagen cell carrier provides a suitable support for the cryopreservation resulting in high survival rates after thawing and providing cells and tissue assemblies already adhered to a mechanically stable and biocompatible support. Frozen collagen carrier-cells assemblies, the frozen artificial cell constructs or three-dimensional complex tissue assemblies obtainable by the method and the use thereof after thawing are also disclosed.Type: ApplicationFiled: February 18, 2010Publication date: March 29, 2012Inventors: Timo Schmidt, Lothar Just, Franz Maser, Holger Becker
-
Publication number: 20120058531Abstract: The present invention concerns a new method for the production of 1,3-propanediol comprising culturing a microorganism on a culture medium with high glycerine content. The invention also concerns a new microorganism, or strain of microorganism, adapted for the production of 1,3-propanediol from medium comprising high glycerine content. The invention also concerns an “adapted microorganism” which glycerol metabolism is directed to 1,3-propanediol production, and which is allowed to grow in the presence of a high concentration of industrial glycerine. The invention also concerns a biosourced 1,3-propanediol obtained by the process thereof. Finally the invention concerns the use of the above described biosourced 1,3-propanediol as extender chain in thermoplastic polyurethane, as monomers in polytrimethylene terephtalate and as a component in cosmetics formulations.Type: ApplicationFiled: May 5, 2010Publication date: March 8, 2012Applicant: METABOLIC EXPLORERInventors: Michel Chateau, Jean-Yves Dubois, Philippe Soucaille
-
Publication number: 20120058087Abstract: The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method for manufacturing said composition. The invention further relates to a kit of parts comprising, inter alia, said composition. The invention also relates to a method for activating a dormant infection.Type: ApplicationFiled: December 18, 2009Publication date: March 8, 2012Applicant: Kobenhavns UniversitetInventors: Morten Rønn Petersen, Anders Miki Bojesen
-
Publication number: 20120053155Abstract: A system and method for reverting the antibiotic tolerance of persister cells. Brominated furanones, which are quorum sensing inhibitors, are used to revert the antibiotic tolerance of persister cells and enhance their susceptibility to antibiotics by up to one hundred fold. Brominated furanones can be used against bacterial persister cells in biofilms or planktonic form.Type: ApplicationFiled: August 9, 2011Publication date: March 1, 2012Applicant: Syracuse UniversityInventors: Dacheng Ren, Jiachuan Pan
-
Publication number: 20120052093Abstract: The present invention relates to methods and compositions for preventing and treating uterine disease, and in particular to vaccines and bacteriophage compositions for treating or preventing puerperal metritis, clinical endometritis and/or subclinical endometritis.Type: ApplicationFiled: April 22, 2010Publication date: March 1, 2012Applicant: CORNELL UNIVERSITYInventor: Rodrigo Carvalho Bicalho
-
Publication number: 20120045475Abstract: The present invention relates to a bacterium attenuated by a mutation in at least one ABC transporter gene wherein the mutation renders the corresponding ABC transporter protein non-functional and wherein the attenuated bacterium persists in a subject.Type: ApplicationFiled: February 17, 2010Publication date: February 23, 2012Applicant: AUSTRALIAN POULTRY CRC PTY LIMITEDInventors: Glenn Francis Browning, Philip Francis Markham, Chi-Wen Tseng
-
Patent number: 8119365Abstract: A bacteria lacking genomic and non-genomic IS elements is provided. The bacteria may be more stable and useful for the production of amino acids, polypeptides, nucleic acids and other products.Type: GrantFiled: April 7, 2006Date of Patent: February 21, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Frederick R. Blattner, John W. Campbell, David Frisch, Guy Plunkett, Gyorgy Posfai
-
Patent number: 8119373Abstract: In the method for separating and purifying histidine from a culture containing the amino acid, the culture containing histidine and microbial cells is charged onto the top of a column filled with a carrier particle whose particle size is 420 ?m or more and which has an ability to adsorb histidine and then an eluent is passed through the column whereby accomplishing the separation and purification of histidine, and preferably in the step mentioned above, a strong acid cation exchange resin is employed as a carrier particle whereby accomplishing the separation and purification of histidine.Type: GrantFiled: March 15, 2007Date of Patent: February 21, 2012Assignee: Kyowa Hakko Bio Co., Ltd.Inventors: Hideki Murata, Noboru Fujii, Kenji Tajima
-
Patent number: 8114654Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs.Type: GrantFiled: August 20, 2010Date of Patent: February 14, 2012Assignee: The Scripps Research InstituteInventors: Lital Alfonta, Peter G. Schultz, Zhiwen Zhang
-
Patent number: 8114649Abstract: L-cysteine is produced by culturing an Escherichia bacterium having L-cysteine producing ability and containing a gene encoding an O-acetylserine sulphydrylase B or MalY regulatory protein that is modified so that cysteine desulfhydrase activity is reduced or eliminated. The bacterium is cultured in a medium to produce and cause accumulation of L-cysteine in the medium, and collecting L-cysteine from the medium.Type: GrantFiled: December 10, 2009Date of Patent: February 14, 2012Assignee: Ajinomoto Co., Inc.Inventors: Hiroshi Takagi, Shigeru Nakamori, Masaru Wada, Hirotada Mori
-
Patent number: 8110670Abstract: Genetically engineered cells and microorganisms are provided that produce products from the fatty acid biosynthetic pathway (fatty acid derivatives), as well as methods of their use. The products are particularly useful as biofuels.Type: GrantFiled: March 28, 2008Date of Patent: February 7, 2012Assignee: LS9, Inc.Inventors: Zhihao Hu, Fernando Valle
-
Patent number: 8101168Abstract: The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention.Type: GrantFiled: July 9, 2009Date of Patent: January 24, 2012Assignee: North Carolina State UniversityInventors: Hosni M. Hassan, Ryan C. Fink, Matthew R. Evans
-
Publication number: 20120015426Abstract: Disclosed are novel bacterial hosts that are capable of high efficiency transformation with methylated and/or unmethylated nucleic acids, and that are bacteriophage resistant. Such bacteria contain: (1) an F? episome that confers high efficiency transformability; (2) one or more mutations that allow transformation of methylated nucleic acids; (3) one or more mutations that allow transformation with unmethylated nucleic acids; and/or (4) one or more mutations that confer resistance to bacteriophage infection. Also disclosed are methods for transforming such bacteria, and kits that contain such bacteria (e.g., that have been made competent for transformation).Type: ApplicationFiled: September 27, 2011Publication date: January 19, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Fredric R. BLOOM, Brian Schmidt
-
Patent number: 8097437Abstract: The instant invention provides highly pure Polysialic acid and process for preparation thereof.Type: GrantFiled: July 13, 2007Date of Patent: January 17, 2012Assignee: Serum Institute of India Ltd.Inventors: Subhash V. Kapre, Umesh Shaligram
-
Publication number: 20120003740Abstract: This document discloses electroporation vessels, electrocompetent cells that have been aliquoted and frozen in electroporation vessels, and a number of other apparatuses, kits, and methods for electroporation. Some embodiments of electroporation vessels described herein may include a pair of opposing walls that are downwardly angled toward one another in a gap between two electrode surfaces. Further embodiments of devices and methods described herein may eliminate the need for an end user to transfer competent cells from a capped tube to electroporation cuvette, thereby saving time and producing less waste.Type: ApplicationFiled: December 28, 2010Publication date: January 5, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Laura Vozza-Brown, Harry Yim, John Cameron, Matthew O'Banion, Adam Scott Henry, Lisa Marie Olivier
-
Publication number: 20120003626Abstract: The present disclosure describes methods for concentrating microorganisms with concentration agents in a sampling device and the sampling device described herein. More specifically, methods for concentrating microorganisms from large volume samples with concentration agents in a sampling device can provide for rapid, low cost, simple (involving no complex equipment or procedures), and/or effective processes under a variety of conditions.Type: ApplicationFiled: December 30, 2009Publication date: January 5, 2012Inventors: Manjiri T. Kshirsagar, Kurt J. Halverson, Neil Percy, James E. Aysta
-
Patent number: 8088620Abstract: The invention relates to optimised micro-organism strains for the biotransformation production of molecules having NADPH-consuming biosynthetic pathways. The inventive strains can be used in NADPH-consuming biotransformation methods. Said strains are characterized in that one or more NADPH-oxidizing activities are limited.Type: GrantFiled: November 5, 2004Date of Patent: January 3, 2012Assignee: Metabolic ExplorerInventors: Gwénaëlle Bestel-Corre, Cédric Boisart, Michel Chateau, Benjamin Gonzalez, Philippe Soucaille, Rainer Figge, Olivier Zink
-
Publication number: 20110313206Abstract: Methods for the fermentative production of four carbon alcohols is provided. Specifically, butanol, preferably isobutanol is produced by the fermentative growth of a recombinant bacterium expressing an isobutanol biosynthetic pathway.Type: ApplicationFiled: December 13, 2010Publication date: December 22, 2011Applicant: BUTAMAX(TM) ADVANCED BIOFUELS LLCInventors: GAIL K. DONALDSON, ANDREW C. ELIOT, DENNIS FLINT, LORI ANN MAGGIO-HALL, VASANTHA NAGARAJAN
-
Patent number: 8080395Abstract: An isolated mutant of coryneform bacteria comprising a gene encodes a polypeptide having 2-methylcitrate dehydratase activity, where the polypeptide comprises an amino acid sequence in which one of the proteinogenic amino acids except L-proline is present at position 272 or a corresponding or comparable position. In addition, an isolated polynucleotide encoding a polypeptide having 2-methylcitrate dehydratase enzymic activity, which comprises at position 272 of the amino acid sequence or a corresponding or comparable position a proteinogenic amino acid except L-proline is described. A method for producing a recombinant coryneform bacterium and L-amino acids. A recombinant microorganism, L-Lysine-containing feed additive, and L-Tryptophan-containing feed additive is also described.Type: GrantFiled: January 19, 2011Date of Patent: December 20, 2011Assignee: Evonik Degussa GmbHInventors: Brigitte Bathe, Caroline Kreutzer, Georg Thierbach
-
Publication number: 20110306083Abstract: Methods are provided for selecting microbial strains with improved properties for fermentation and/or bioproduct production. A salt selection is employed to identify mutants with improved bioproduct tolerance, titer, or osmotic tolerance relative to a microbial strain from which they were derived.Type: ApplicationFiled: June 13, 2011Publication date: December 15, 2011Applicant: Cobalt Technologies, Inc.Inventor: Jeanette M. MUCHA
-
Patent number: 8076111Abstract: An organic acid is produced by allowing a bacterium which has an ability to produce an organic acid and has been modified so that expression of yidE gene is enhanced, or a product obtained by processing the bacterium, to act on an organic raw material in a reaction mixture containing carbonate ions, bicarbonate ions, or carbon dioxide gas to produce the organic acid, and collecting the organic acid.Type: GrantFiled: October 15, 2009Date of Patent: December 13, 2011Assignee: Ajinomoto Co., Inc.Inventors: Keita Fukui, Yoshinori Tajima, Kazue Kawamura, Yoshihiro Usuda, Kazuhiko Matsui
-
Patent number: 8071339Abstract: The present invention relates to a mutant bacterial PRPP synthetase which is resistant to feedback by purine nucleotides, and a method for producing L-histidine using the bacterium of the Enterobacteriaceae family wherein the L-amino acid productivity of said bacterium is enhanced by use of the PRPP synthetase which is resistant to feedback by purine nucleotides, coded by the mutant prsA gene.Type: GrantFiled: February 15, 2008Date of Patent: December 6, 2011Assignee: Ajinomoto Co., Inc.Inventors: Elena Vitalievna Klyachko, Rustem Saidovich Shakulov, Yuri Ivanovich Kozlov
-
Patent number: 8067179Abstract: Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain. Screening methods that employ genetic packages such as bacteria and bacteriophages enable high through-put identification of ligand binding molecules.Type: GrantFiled: November 30, 2007Date of Patent: November 29, 2011Assignee: Research Development FoundationInventors: George Georgiou, Yariv Mazor
-
Publication number: 20110286916Abstract: The present invention relates to mammalian antibodies, preferably fully human monoclonal antibodies and antigen-binding portions thereof that specifically bind to a cell surface receptor, wherein the receptor protein is a Notch1 receptor protein. Some of the disclosed antibodies bind Notch1 to the exclusion of other members of the Notch receptor family, while other antibodies bind Notch 1 and Notch3. Nucleic acid molecules encoding the Notch antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of Notch1 or Notch3 including aberrant activation of each of these receptors.Type: ApplicationFiled: November 16, 2009Publication date: November 24, 2011Inventors: Jose Miguel Aste-Amezaga, Ningyan Zhang, Fubao Wang, Andrew Bett, Anna Demartis, Maurizio Nuzzo, Paolo Monaci, Stephen Blacklow, Jon Aster
-
Publication number: 20110269198Abstract: The invention pertains to a method for preparing cells that can be used as biocatalysts by inducing in them a growth-decoupled state, in which interferase inhibits the expression of genes except the ones that code for the pathway enzymes of interest. mRNAs that code for interferase-resistant products are overexpressed in the background of a metabolically-frozen cell. Enzymes that compete for a substrate or product of the pathway of interest may be altered such that the enzyme is sensitive to a site-specific protease, which protease is inducible in the host cell.Type: ApplicationFiled: December 14, 2009Publication date: November 3, 2011Applicant: GREENLIGHT BIOSCIENCES, INC.Inventor: Daniel Klein-Marcuschamer
-
Publication number: 20110269213Abstract: Novel fungal endoglucanases Cel5 and Cel2 are disclosed. The endoglucanases are conveniently produced by recombinant technology, and means for their production are described. The endoglucanases are used for treating cellulosic material, especially in textile industry, e.g. in biofinishing or biostoning. They may also be used in detergents, in animal feed and/or in pulp and paper industry, or in hydrolysis of lignocellulosic material for, e.g. bioethanol production.Type: ApplicationFiled: December 28, 2009Publication date: November 3, 2011Inventors: Terhi Puranen, Leena Valtakari, Marika Alapuranen, George Szakacs, Pentti Ojapalo, Jari Vehmaanperä
-
Publication number: 20110269212Abstract: Novel fungal endoglucanases with substantial performance at low temperatures are disclosed. The endoglucanases are conveniently produced by recombinant technology, and means for their production are described. The endoglucanases are used for treating cellulosic material, especially in textile industry, e.g. in biofinishing or biostoning. They may also be used in detergents, in animal feed and/or in pulp and paper industry or bioethanol production.Type: ApplicationFiled: December 28, 2009Publication date: November 3, 2011Applicant: AB Enzymes OyInventors: Leena Valtakari, Marika Alapuranen, George Szakacs, Jarno Kallio, Pentti Ojapalo, Jari Vehmaanperä, Terhi Puranen
-
Publication number: 20110268773Abstract: The present invention relates to an isolated inclusion body comprising a polypeptide, characterised in that such inclusion body is in particulate form. The present invention also refers to a bacterial cell comprising said inclusion body. The present invention additionally refers to a composition comprising said inclusion body and a eukaryotic cell. The present invention moreover refers to a composition comprising said inclusion body and animal or plant tissue. The present invention furthermore refers to the uses of said inclusion body as medicaments and cell-proliferation stimulators and tissue regenerators.Type: ApplicationFiled: December 22, 2009Publication date: November 3, 2011Applicants: UNIVERSITAT AUTÒNOMA DE BARCELONA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICASInventors: Jaume Veciana Miro, Inmaculada Ratera Bastardas, César Díez Gil, Antonio Pedro Villaverde Corrales, Esther Vázquez Gómez, Elena García Fruitós
-
Publication number: 20110262410Abstract: The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.Type: ApplicationFiled: July 8, 2011Publication date: October 27, 2011Applicant: Valorisation - Recherche, Limited PartnershipInventors: Eric Nadeau, John Morris Fairbrother
-
Patent number: 8043842Abstract: The present invention provides a bacterium having a genome that is genetically engineered to be at least 2 to 14% smaller than the genome of its native parent strain. A bacterium with a smaller genome can produce a commercial product more efficiently. The present invention also provides methods for deleting genes and other DNA sequences from a bacterial genome. The methods provide precise deletions and seldom introduces mutations to the genomic DNA sequences around the deletion sites. Thus, the methods can be used to generate a series of deletions in a bacterium without increasing the possibility of undesired homologous recombination within the genome. In addition, some of the methods provided by the present invention can also be used for replacing a region of a bacterial genome with a desired DNA sequence.Type: GrantFiled: July 1, 2005Date of Patent: October 25, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Frederick R. Blattner, Gyorgy Posfai, Christopher D. Herring, Guy Plunkett, Jeremy D. Glasner
-
Publication number: 20110256576Abstract: The present invention is directed to the recovery of bacteria and microparasites, particularly Cryptosporidium and Giardia, from water samples by filtration through a mixed cellulose ester membrane, partial dissolution of said membrane with methanol followed by completion in the presence of acetone, and purification and concentration using glass beads as a secondary confinement matrix.Type: ApplicationFiled: October 14, 2009Publication date: October 20, 2011Applicant: Universite LavalInventors: Luc Bissonnette, Andrée F. Maheux, Michel G. Bergeron, Maurice Boissinot, Jean-Luc Bernier
-
Publication number: 20110256583Abstract: A reagent mixture and testing procedure for accelerating mixing of the formulation with a specimen sample being tested by effervescing when hydrolized, thereby causing an internal “stirring” of the reagent and the specimen sample. Examples of specimen samples that can be tested include nasal swabs and lesion swabs, environmental swabs, foodstuffs, and water, to mention a few.Type: ApplicationFiled: March 23, 2011Publication date: October 20, 2011Inventor: Stephen C. Edberg
-
Patent number: 8039243Abstract: The present invention provides a bacterium having a genome that is genetically engineered to be smaller than the genome of its native parent strain. A bacterium with a smaller genome can produce a commercial product more efficiently. The present invention also provides methods for deleting genes and other DNA sequences from a bacterial genome. The methods provide precise deletions and seldom introduces mutations to the genomic DNA sequences around the deletion sites. Thus, the methods can be used to generate a series of deletions in a bacterium without increasing the possibility of undesired homologous recombination within the genome. In addition, some of the methods provided by the present invention can also be used for replacing a region of a bacterial genome with a desired DNA sequence.Type: GrantFiled: December 9, 2005Date of Patent: October 18, 2011Assignee: Wisconsin Alumni Research FoundationInventor: Frederick R. Blattner
-
Publication number: 20110236929Abstract: The present invention relates to a novel non-pathogenic Escherichia coli (E. coli) B BL21 strain comprising a deletion of group II capsular gene cluster, and the use thereof for the production of peptides.Type: ApplicationFiled: November 10, 2009Publication date: September 29, 2011Applicant: Novo Nordisk A/SInventors: Helle Fabricius Wöldike, Jianhui Deng, Xin Zhao, Yun Liu, Jing Su
-
Publication number: 20110224097Abstract: Viable Gram-negative bacteria or components thereof comprising outer membranes that substantially lack a ligand, such as Lipid A or 6-acyl lipidpolysaccharide, that acts as an agonist of TLR4/MD2. The bacteria may comprise reduced activity of arabinose-5-phosphate isomerases and one or more suppressor mutations, for example in a transporter thereby increasing the transporters capacity to transport Lipid IVA or in membrane protein YhjD. One or more genes (e.g., IpxL, IpxM, pagP, IpxP, and/or eptA) may be substantially deleted and/or one or more enzymes (e.g., LpxL, LpxM, PagP, LpxP, and/or EptA) may be substantially inactive. The bacteria may be competent to take up extracellular DNA, may be donor bacteria, or may be members of a library. The present invention also features methods of creating and utilizing such bacteria.Type: ApplicationFiled: March 11, 2011Publication date: September 15, 2011Applicant: RESEARCH CORPORATION TECHNOLOGIESInventors: David Bramhill, Uwe Mamat
-
Publication number: 20110212458Abstract: The invention provides biosynthetic routes to xylitol production that do not require pure D-xylose for synthesis and that can utilize inexpensive substrates such as hemicellulose hydrolysates.Type: ApplicationFiled: May 11, 2011Publication date: September 1, 2011Inventors: Paul Taylor, Ian Fotheringham, Nathan Wymer, Badal Saha, David Demirjian, Yoshikiyo Sakaibara, Francis Michael Racine